Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1022, pseudogene (RNU6-1022P) is a processed pseudogene of the U6 small nuclear RNA (snRNA) in the human genome[2][4][5]. U6 snRNA itself is a non-coding RNA component of the spliceosome involved in pre-mRNA splicing[1][3], but the pseudogene copy (RNU6-1022P) does not encode functional RNA and is not involved in biological processes or disease, nor is it a direct therapeutic target[2][4][5]. U6 snRNA pseudogenes such as RNU6-1022P are typically formed via retrotransposition (often LINE/L1-mediated), serve as evolutionary markers of genome dynamics, and generally lack known biological function, therapeutic relevance, or drug interactions[4]. The presence of "pseudogene" in the full name and lack of an associated protein or functional RNA makes this distinct from canonical molecular targets, meaning this entry is not a valid therapeutic target and should be labeled as biologically inactive (incorrect as a drug target)[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1022, pseudogene (RNU6-1022P).